Cardiff Oncology Yönetim
Yönetim kriter kontrolleri 3/4
Cardiff Oncology CEO'su Mark Erlander, May2020 tarihinde atandı, in görev süresi 4.5 yıldır. in toplam yıllık tazminatı $ 1.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 38.4% maaş ve 61.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.048% ine doğrudan sahiptir ve bu hisseler $ 59.98K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 10.2 yıldır.
Anahtar bilgiler
Mark Erlander
İcra Kurulu Başkanı
US$1.5m
Toplam tazminat
| CEO maaş yüzdesi | 38.4% |
| CEO görev süresi | 4.5yrs |
| CEO sahipliği | 0.05% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 10.2yrs |
Son yönetim güncellemeleri
Recent updates
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$2m | US$594k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$2m | US$571k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$4m | US$533k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$1m | US$445k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$853k | US$399k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$909k | US$387k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 31 2017 | US$1m | US$374k | -US$25m |
Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 1.55M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.07K ).
Tazminat ve Kazançlar: Mark 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Mark Erlander (64 yo)
4.5yrs
Görev süresi
US$1,547,772
Tazminat
Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$1.55m | 0.048% $ 60.0k | |
| Chief Financial Officer | 3.3yrs | US$917.72k | 0.12% $ 147.0k | |
| Chief Medical Officer | 1.8yrs | US$1.26m | 0% $ 0 | |
| Chief Scientific Officer | 2.8yrs | US$4.17m | 0% $ 0 | |
| VP of Finance & Administration | 9.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Finance | 1.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim: CRDF 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$1.55m | 0.048% $ 60.0k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 4.6yrs | US$114.43k | 1.36% $ 1.7m | |
| Member of Scientific Advisory Board | 10.3yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 12yrs | US$35.85k | Veri yok | |
| Independent Chairman of the Board | 10.8yrs | US$154.43k | 0.061% $ 76.1k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 14.6yrs | Veri yok | Veri yok | |
| Independent Director | 4.6yrs | US$116.43k | 0.22% $ 278.8k | |
| Member of Scientific Advisory Board | 10.2yrs | Veri yok | Veri yok | |
| Independent Director | 3.4yrs | US$110.43k | 0.020% $ 24.5k | |
| Member of Scientific Advisory Board | 14.6yrs | Veri yok | Veri yok |
10.2yrs
Ortalama Görev Süresi
72yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: CRDF 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.2 yıldır).